

- 40) Weiss LW, Clark FC. *Three protocols for measuring subcutaneous fat thickness on the upper extremities*. Eur J Appl Physiol. 1987;56(2):217-21. PMID: 3552659; UI: 87190331
- 41) Heitmann BL et al., *Evaluation of body fat estimated from body mass index, skinfolds and impedance. A comparative study*. Eur J Clin Nutr 1990 Nov;44(11):831-7
- 42) Hermans P, Clumeck N, Picard O. et. al., *AIDS-related Kaposi's sarcoma patients with visceral manifestations. Response to human chorionic gonadotropin preparations*. J Hum Virol Jan-Feb;1(2):82-9. 1998
- 43) LaPorte DJ. *Predicting attrition and adherence to a very low calorie diet: a prospective investigation of the eating inventory*. Int J Obes 1990 Mar;14(3):197-206
- 44) LaPorte DJ. *Treatment response in obese binge eaters: preliminary results using a very low calorie diet (VLCD) and behavior therapy*. Addict Behav 1992;17(3):247-57
- 45) Leshem Y. et al., *Gonadotropin promotion of adventitious root production on cuttings of Begonia semperflorens and Vitis vinifera*. Plant Physiol. 1968 Mar;43(3):313-7
- 46) Lustbader JW. et al., *Structural and molecular studies of human chorionic gonadotropin and its receptor*. Recent Prog Horm Res. 1998;53:395-424
- 47) Malkin A. *The presence of glycosylated, biologically active chorionic gonadotropin in human liver*. Clin Biochem 1985 Apr;18(2):75-7
- 48) Maruo T. et al., *Production of Choriogonadotropin-like factor by a microorganism*. Proc Natl Acad Sci U S A. 1979 Dec;76(12):6622-6
- 49) McGarvey ME, Tulpule A. et. al., *Emerging treatments for epidemic (AIDS-related) Kaposi's sarcoma*. Curr Opin Oncol Sep;10(5):413-21 1998
- 50) Miller R. et al., *A clinical study of the use of human chorionic gonadotrophin in weight reduction*. J Fam Pract. 1977 Mar;4(3):445-8
- 51) Morgan FJ. et al., *Chemistry of human chorionic gonadotropin*. Monograph. 1976 May 25
- 52) Mueller WH. *Relative reliability of circumferences and skinfolds as measures of body fat distribution*. Am J Phys Anthropol 1987 Apr;72(4):437-9
- 53) Niebroj TK. et al., *Effect of chorionic gonadotropins administration on water metabolism in glaucomatous women*. Endokrynol Pol. 1971 May-Jun;22(3):251-5
- 54) Orphanidou C. *Accuracy of subcutaneous fat measurement: comparison of skinfold calipers, ultrasound, and computed tomography*. J Am Diet Assoc 1994 Aug;94(8):855-8
- 55) Orphanidou CI, McCargar LJ, Birmingham CL, Belzberg AS. *Changes in body composition and fat distribution after short-term weight gain in patients with anorexia nervosa*. Am J Clin Nutr. 1997 Apr ; 65 (4) :1034-41
- 56) Perniola R. et al., *Human chorionic gonadotrophin therapy in hypogonadal thalassaemic patients with osteopenia: increase in bone mineral density*. J Pediatr Endocrinol Metab. 1998;11 Suppl 3:995-6
- 57) Pickar D et al., *Clinical studies of the endogenous opioid system*. Biol Psychiatry 1982 Nov;17(11):1243-76
- 58) Pierce JG.. Eli Lilly lecture. *The subunits of pituitary thyrotropin--their relationship to other glycoprotein hormones*. Endocrinology. 1971 Dec;89(6):1331-44
- 59) Rabe T. et al., *Risk-benefit analysis of a hCG-500 kcal reducing diet (cura romana) in females*. Geburtshilfe Frauenheilkd. 1987 May;47(5):297-307
- 60) Reiss M.. *Stunted growth and the mechanism of its stimulation in mentally disturbed adolescents*. Int J Neuropsychiatry. 1965 Aug;1(4):313-7
- 61) Rivlin RS.. *Therapy of obesity with hormones*. N Engl J Med. 1975 Jan 2;292(1):26-9
- 62) Ross GT.. *Clinical relevance of research on the structure of human chorionic gonadotropin*. Am J Obstet Gynecol. 1977 Dec 1;129(7):795-808
- 63) Sanders S, Norman AP. *Chorionic gonadotrophin in male growth-retarded adolescent asthmatic patients*. Practitioner. 1973 May;210(259):690-2.
- 64) Sarma JM, Houghten RA. *Enzyme linked immunosorbent assay (ELISA) for beta-endorphin and its antibodies*. Life Sci 1983;33 Suppl 1:129-32
- 65) Sarria A et al., *Skinfold thickness measurements are better predictors of body fat percentage than body mass index in male Spanish children and adolescents*. Eur J Clin Nutr 1998 Aug;52(8):573-6
- 66) Scaffidi A. *Data on the pathogenesis and therapy of bronchial asthma in patients with secondary hypogonadism*. Minerva Med Dec 1;65(86):4473-6 1974
- 67) Segal SJ (ed.). *Chorionic Gonadotropin*. Plenum Press: NY. 1980
- 68) Shetty KR. et al., *Human chorionic gonadotropin (HCG) treatment of obesity*. Arch Intern Med. 1977 Feb;137(2):151-5
- 69) Shomer-Ilan A. et al., *Further evidence for the presence of an endogenous gonadotrophin-like plant factor: "phytostrophin." Isolation and mechanism of action of the active principle*. Aust J Biol Sci. 1973 Feb;26(1):105-12
- 70) Simeons ATW. *The action of chorionic gonadotropin in the obese*. Lancet II:1954: 946-947
- 71) Simeons ATW.. *Pounds and Inches: A new approach to obesity*. Private Printing (1976)
- 72) Stein MR. et al., *Ineffectiveness of human chorionic gonadotropin in weight reduction: a double-blind study*. Am J Clin Nutr. 1976 Sep;29(9):940-8
- 73) Stern JS. *Weight control programs*. Curr Concepts Nutr. 1977;5:137-55
- 74) Suginami H. et al., *Immunohistochemical localization of a human chorionic gonadotropin-like substance in the human pituitary gland*. J Clin Endocrinol Metab. 1982 Dec;55(6):1161-6
- 75) Tagliabue A et al., *Application of bioelectric impedance measurement in the evaluation of body fat*. Recent Prog Med 1989 Feb;80(2):59-62
- 76) Talbot LA et al., *Assessing body composition: the skinfold method*. AAOHN J 1995 Dec;43(12):605-13
- 77) Tavio M, Nasti G, Simonelli C. et. al., *Human chorionic gonadotropin in the treatment of HIV-related Kaposi's sarcoma*. Eur J Cancer Sep;34(10):1634-7 1998
- 78) Torgerson JS et al., *VLCD plus dietary and behavioral support versus support alone in the treatment of severe*
(Continued on next page)